S & P Pharmaceutical Co., Ltd. (formerly known as Qinghai Sanpu Pharmaceutical Co., Ltd.) by the Department of Economic Restructuring Office of Qinghai Province [1994] No. No. 021 approved in 1994. In May 17 ways to raise the establishment of the corporation. August 11, 1994 by the China Securities Regulatory Commission issued the word [1994] No. 30 approved the issue of shares to the public, and in February 6th, 1995 at the Shanghai Stock Exchange, stock code "600869." Registered Address: Xining, Qinghai Road, East District, Delhi 58, Statutory representative: Xipei, registration number: 630000100009098. There's the Far East Cable Co., Ltd. subsidiary, Jiangsu Far East Cable Co., Ltd., Far East Composite Technology Co., Ltd., Qinghai Pharmaceutical Co., Ltd., Shanghai Polaris Enterprise Development Co., Ltd..
Company was founded in 1969 in Qinghai Chinese Pharmaceutical Factory. After years of exploration and hard work, has become the largest in Qinghai Province, Tibetan medicine production base. The company has the treatment of cardiovascular system, respiratory system and the other three categories of health care products in more than 100 varieties. The main products of hepatitis B three general health tablets, capsules three general cardiovascular Yan, three Plymouth lung slices, three general Qi wind particles, three general Rhodiola capsules are measured using local natural medicinal Qinghai refined.
2010 September, non-public offering of shares to buy assets cum significant asset restructuring (related party transactions) by the China Securities Regulatory Commission successfully achieve the Far East cable listing of assets, the company's total share capital of 120 million yuan to 42743.2684 million. Through this operation, three general medicine along with the cable industry companies turned a new leader, become a power cable, electrical equipment, wire and cable, bare wire, carbon fiber composite core wire and other four major categories of soft aluminum wire and cable products and natural plant drug production and sales of the two main listed companies to optimize and adjust the S & P Pharmaceutical's core business, expand business, to the three general medicine to bring new profit growth point for the three general medicine to achieve healthy, stable , laid the foundation for rapid growth.
